Inducible P27Kip1 expression inhibits proliferation of K562 cells and protects against apoptosis induction by proteasome inhibitors

被引:23
作者
Drexler, HCA [1 ]
Pebler, S [1 ]
机构
[1] Max Planck Inst Physiol & Clin Res, Dept Mol Cell Biol, D-61231 Bad Nauheim, Germany
关键词
apoptosis; cell cycle; leukemia; p27(Kip1); proteasome inhibitor;
D O I
10.1038/sj.cdd.4401159
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Overexpression of the cyclin-dependent kinase inhibitor P27(Kip1) has been demonstrated to induce cell cycle arrest and apoptosis in various cancer cell lines, but has also been associated with the opposite effect of enhanced survival of tumor cells and increased resistance towards chemotherapeutic treatment. To address the question of how p27(KIP1) expression is related to apoptosis induction, we studied doxycycline-regulated p27(KiP1) expression in K562 erythroleukemia cells. p27(KiP1) expression effectively retards proliferation, but it is not sufficient to induce apoptosis in K562 cells. p27(Kip1)-expressing K562 cells, however, become resistant to apoptosis induction by the proteasome inhibitors PSI, MG132 and epoxomicin, in contrast to wild-type K562 cells that are efficiently killed. Cell cycle arrest in the S phase by aphidicolin, which is not associated with an accumulation. of p27(Kip1) protein, did not protect K562 cells against the cytotoxic effect of the proteasome inhibitor PSI. The expression levels of p27(Kip1) thus constitute an important parameter, which decides on the overall sensitivity of cells against the cytotoxic effect of proteasome inhibitors.
引用
收藏
页码:290 / 301
页数:12
相关论文
共 78 条
[11]   p53-mediated downregulation of Chk1 abrogates the DNA damage-induced G2M checkpoint in K562 cells, resulting in increased apoptosis [J].
Cummings, M ;
Siitonen, T ;
Higginbottom, K ;
Newland, AC ;
Allen, PD .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) :421-428
[12]   Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR-ABL tyrosine kinase, CGP 57148 [J].
Dan, S ;
Naito, M ;
Tsuruo, T .
CELL DEATH AND DIFFERENTIATION, 1998, 5 (08) :710-715
[13]   p53 expression in K562 cells is associated with caspase-mediated cleavage of c-ABL and BCR-ABL protein kinases [J].
Di Bacco, AMA ;
Cotter, TG .
BRITISH JOURNAL OF HAEMATOLOGY, 2002, 117 (03) :588-597
[14]   p53-dependent cell cycle arrest induced by N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts [J].
Dietrich, C ;
Bartsch, T ;
Schanz, F ;
Oesch, F ;
Wieser, RJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (20) :10815-10819
[15]  
Dimanche-Boitrel MT, 2000, ANTICANCER RES, V20, P849
[16]   Inhibition of proteasome function induces programmes cell death in proliferating endothelial cells [J].
Drexler, HCA ;
Risau, W ;
Konerding, MA .
FASEB JOURNAL, 2000, 14 (01) :65-77
[17]   Activation of the cell death program by inhibition of proteasome function [J].
Drexler, HCA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (03) :855-860
[18]   Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].
Druker, BJ ;
Sawyers, CL ;
Kantarjian, H ;
Resta, DJ ;
Reese, SF ;
Ford, JM ;
Capdeville, R ;
Talpaz, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042
[19]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[20]   INDUCTION OF APOPTOSIS IN FIBROBLASTS BY C-MYC PROTEIN [J].
EVAN, GI ;
WYLLIE, AH ;
GILBERT, CS ;
LITTLEWOOD, TD ;
LAND, H ;
BROOKS, M ;
WATERS, CM ;
PENN, LZ ;
HANCOCK, DC .
CELL, 1992, 69 (01) :119-128